The CACNA2D2 antibody is a tool used to detect the CACNA2D2 protein, a subunit of voltage-gated calcium channels (VGCCs) that plays a critical role in regulating calcium influx and cellular excitability. Encoded by the *CACNA2D2* gene, this protein belongs to the α2δ subunit family, which includes four members (α2δ-1 to α2δ-4) that modulate the trafficking and biophysical properties of VGCCs. CACNA2D2 is predominantly expressed in the brain, heart, and endocrine tissues, where it influences synaptic transmission, hormone secretion, and cardiac function.
Studies suggest CACNA2D2 may act as a tumor suppressor in certain cancers, with reduced expression linked to poor prognosis in lung and breast cancers. Additionally, mutations or dysregulation of *CACNA2D2* have been associated with neurological disorders, including epilepsy and neuropathic pain. The CACNA2D2 antibody is widely used in research to investigate protein expression patterns, subcellular localization, and its interaction with other calcium channel subunits (e.g., Cavα1). It is applied in techniques such as Western blotting, immunohistochemistry, and immunofluorescence.
Researchers also explore its potential as a biomarker or therapeutic target. However, specificity challenges may arise due to homology among α2δ subunits, necessitating validation via knockout controls. Recent work highlights its role in calcium signaling pathways and disease mechanisms, driving interest in developing antibodies with high affinity and minimal cross-reactivity.